Ex-Celgene chief Mark Alles, former Goldfinch Bio leader Tony Johnson are back in the game as CEOsnews2024-01-12T10:57:43+00:00January 12th, 2024|Endpoints News|
J&J extends ‘Save Legs’ campaign to drive awareness of peripheral artery diseasenews2024-01-11T20:39:07+00:00January 11th, 2024|Endpoints News|
Novartis reportedly backs off acquisition of Cytokinetics – WSJnews2024-01-11T19:43:47+00:00January 11th, 2024|Endpoints News|
Biogen ends agreement with Acorda for multiple sclerosis drug Fampyranews2024-01-11T19:11:20+00:00January 11th, 2024|Endpoints News|
Want to make better pharma ads? Try using humor and more branding, Kantar analyst saysnews2024-01-11T18:51:21+00:00January 11th, 2024|Endpoints News|
FDA determines GLP-1s not linked to suicidal thoughts or actions in preliminary reviewnews2024-01-11T18:39:08+00:00January 11th, 2024|Endpoints News|
FDA develops pilot to harmonize international gene therapy regulationsnews2024-01-11T18:01:28+00:00January 11th, 2024|Endpoints News|
Praxis prices $150M public stock offering with four topline readouts expected in 2024news2024-01-11T16:32:08+00:00January 11th, 2024|Endpoints News|
WuXi Bio expands US presence; FujiFilm boosts autoinjector services; SpectronRx to make prostate cancer radioligandnews2024-01-11T16:23:58+00:00January 11th, 2024|Endpoints News|
Case against Gilead for delaying release of safer HIV drug on solid ground, court rulesnews2024-01-11T16:19:58+00:00January 11th, 2024|Endpoints News|
